MedTrace Logo

A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients

NCT00929981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2019-01-02

Study results available
· View outcomes & findings →

Summary

This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life effectiveness and tolerability of Medrol in treating contact dermatitis in Indian patients. Patients with contact dermatitis who have been prescribed for Medrol will be enrolled into the study and will be followed up for the resolution of symptoms

Conditions

  • Dermatitis, Contact

Interventions

DRUG

Tablet Methylprednisolone (4 or 16 mg)

Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00929981 on ClinicalTrials.gov